Clocortolone Pivalate

Summary

Clocortolone Pivalate (CHEMBL1200975) is an approved small-molecule anti-inflammatory drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 495 Da · C27H36ClFO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200975
Name	Clocortolone Pivalate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5282493
ChEBI	CHEBI:59583
Molecular formula	C27H36ClFO5
Molecular weight	495
InChIKey	SXYZQZLHAIHKKY-GSTUPEFVSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C(C)(C)C)C)O)Cl)C)F

IUPAC name: [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate

ChEBI definition: The 21-O-pivalate ester of clocortolone. It is used for the relief of inflammatory and pruritic (itching) skin disorders.

Pharmacological roles (ChEBI): anti-inflammatory drug, antipruritic drug.

Also known as: Clocortolone pivalate, Cloderm, SH 863, SH-863, CLOCORTOLONE PIVALATE, SID56463639, SID144204183, CLOCORTOLONE-PIVALATE, clocortolone-pivalate, clocortolone pivalate

Patent coverage: 2,931 distinct patent families (11,614 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Androgen receptor, Progesterone receptor, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	7.93	AC50	11.8	nM	CHEMBL_ACT_25204807
AR	7.08	AC50	83.3	nM	CHEMBL_ACT_25203874
ADORA3	5.26	AC50	5524	nM	CHEMBL_ACT_25199129

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01714544	PHASE4	COMPLETED	Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
NCT04358770	PHASE1	COMPLETED	Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).